Artificial Intelligence and Circulating Abnormal Cells: Auxiliary Diagnosis in Differentiating Benign From Malignant Pulmonary Nodule in China

Auxiliary Diagnosis in Differentiating Benign From Malignant Pulmonary Nodule in China

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000034812

Enrollment

Unknown

Registered

2020-07-20

Start date

2020-07-31

Completion date

Unknown

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary nodules

Interventions

Gold Standard:Pathological diagnosis

Index test:Artificial&#32

Intelligence,Circulating&#32

Abnormal&#32

Cells,&#32

MDA&#32

TEST.

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with age >= 40 years old; 2. The patients with occupational exposure risk of environmental pollution have full-time working experience of more than 5 years and average working hours of more than 35 hours per week; 3. Men and women are not limited.

Exclusion criteria

Exclusion criteria: 1. Patients who have a clear history of cancer (except lung cancer), or are currently receiving or have received any form of anti-tumor treatment; 2. Patients with severe cardiopulmonary disease.

Design outcomes

Primary

Measure	Time frame
CAC;LDCT;SEN, SPE, ACC, AUC of ROC;	—

Secondary

Measure	Time frame
CEA;CYFRA21-1;PRO-GRP;	—

Contacts

Public ContactBaishen Chen

Zhuhai SanMed Biotech Ltd.

pason06213367@163.com+86 13560471611

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026